Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
Autoimmune Retinopathy: Symptoms and Management
Autoimmune retinopathy (AIR) is a rare group of diseases characterized by retinal degeneration due to autoimmune mechanisms. There are two primary types of AIR: paraneoplastic retinopathy, associated with an underlying malignancy, and non-paraneoplastic autoimmune retinopathy (npAIR), which occurs independently of…
What is Vitritis and How to Manage it?
Vitritis is an ocular condition characterized by inflammation of the vitreous, a gel-like substance filling the eyeball behind the lens and in front of the retina. This inflammation can be due to various causes, including infections, autoimmune diseases, or trauma…
What is Schirmer’s Test and How to Conduct it
In the dynamic landscape of ophthalmology, the evaluation of tear production holds a central position in understanding and managing a spectrum of ocular conditions. Among the various tools available, Schirmer’s Test, named after the pioneering German ophthalmologist Otto Schirmer, stands…
Role of Corneal Hysteresis in Glaucoma Risk Assessment
What is Corneal Hysteresis? Corneal hysteresis is a measure of the cornea’s ability to absorb and dissipate energy when subjected to stress, such as the pressure exerted within the eye. The cornea is the clear, dome-shaped front surface of the…
EyeBio Raises $130M for Restoret Development
EyeBio announced the successful completion of an extension to its Series A financing, resulting in a total raised amount of $130 million to date. The funding will be utilized by EyeBio to accelerate the company’s clinical development program and expand…
VSY Biotechnology to Introduce a Novel Anti-VEGF for AMD
VSY Biotechnology GmbH is proud to announce the groundbreaking development of Varliciment, a revolutionary anti-VEGF agent for the treatment of age-related macular degeneration (AMD). Varliciment distinguishes itself from existing anti-VEGF agents like brolucizumab, namely Novartis’ Beovu, by being non-generic. This…
World’s First Whole-Eye and Face Transplant Breakthrough
In a groundbreaking medical feat, a surgical team comprising more than 140 clinicians, including surgeons, nurses, and various healthcare professionals from New York University (NYU) Langone Health, has successfully conducted the world’s first whole-eye and partial face transplantation on a…
AMD Forecast: New Algorithm Offers 94% Accuracy
Researchers at Duke University have developed a computer program that can predict with 94% accuracy whether an individual’s age-related macular degeneration (AMD) will deteriorate within a year. The deep learning algorithm, featured in an article within JAMA Ophthalmology, evaluates comprehensive…
Blind Canvas Project by Ora and BlindCAN Film Festival
Ora and the BlindCAN Film Festival have jointly unveiled The Blind Canvas Project, an initiative that leverages the capabilities of storytelling and generative artificial intelligence (AI) to cultivate a more profound comprehension of the lives and narratives of individuals affected…
Ocular Therapeutix Gets FDA Agreement for Wet AMD Trial
Ocular Therapeutix has obtained written FDA approval for the comprehensive design of its pivotal phase 3 clinical trial, known as the SOL trial, which evaluates Axpaxli (axitinib intravitreal implant) for treating wet age-related macular degeneration (AMD) under a Special Protocol…